Subclinical hyperthyroidism is associated with increased risk of coronary heart disease (CHD) morbidity and mortality; and treatment with levothyroxine for subclinical hypothyroidism is associated with fewer ischemic heart disease (IHD) events in patients aged 40-70 years.
Advanced age is a risk factor for complications after thyroidectomy.
Boca Pharmacal has received approval from the FDA for Methimazole Tablets USP, the generic version of King Pharmaceutical’s Tapazole tablets.
Screening for maternal hypothyroidism, and treatment of women with positive results, is not associated with improved IQ in offspring at age 3.
NPS Pharmaceuticals announced positive results from its Phase 3 REPLACE study of NPSP558 for the treatment of hypoparathyroidism in adults.
Cytochroma announced initiation of its Phase 2b study of CTAP101 capsules for the treatment of patients with vitamin D insufficiency, secondary hyperparathyroidism (SHPT), and stage 3 CKD.
The FDA has added a Boxed Warning to the label for propylthiouracil, to include information about reports of severe liver injury and acute liver failure, some of which have been fatal, in adult and pediatric patients using this medication.
